The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study by Goodall, Gordon et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Endocrine Disorders
Open Access Research article
The consequences of delaying insulin initiation in UK type 2 diabetes 
patients failing oral hyperglycaemic agents: a modelling study
Gordon Goodall*1, Eric M Sarpong2, Clarice Hayes2 and William J Valentine3
Address: 1IMS Health, Allschwil, Switzerland, 2Global Health Outcomes, Eli Lilly & Co., Indianapolis, USA and 3Ossian Health Economics and 
Communications, Basel, Switzerland
Email: Gordon Goodall* - ggoodall@ch.imshealth.com; Eric M Sarpong - sarpong_eric@lilly.com; Clarice Hayes - hays_clarice@lilly.com; 
William J Valentine - valentine@ossianconsulting.com
* Corresponding author    
Abstract
Background: Recent data have shown that type 2 diabetes patients in the UK delay initiating
insulin on average for over 11 years after first being prescribed an oral medication. Using a
published computer simulation model of diabetes we used UK-specific data to estimate the clinical
consequences of immediately initiating insulin versus delaying initiation for periods in line with
published estimates.
Methods: In the base case scenario simulated patients, with characteristics based on published UK
data, were modelled as either initiating insulin immediately or delaying for 8 years. Clinical
outcomes in terms of both life expectancy and quality-adjusted life expectancy and also diabetes-
related complications (cumulative incidence and time to onset) were projected over a 35 year time
horizon. Treatment effects associated with insulin use were taken from published studies and
sensitivity analyses were performed around time to initiation of insulin, insulin efficacies and
hypoglycaemia utilities.
Results: For patients immediately initiating insulin there were increases in (undiscounted) life
expectancy of 0.61 years and quality-adjusted life expectancy of 0.34 quality-adjusted life years
versus delaying initiation for 8 years. There were also substantial reductions in cumulative incidence
and time to onset of all diabetes-related complications with immediate versus delayed insulin
initiation. Sensitivity analyses showed that a reduced delay in insulin initiation or change in insulin
efficacy still demonstrated clinical benefits for immediate versus delayed initiation.
Conclusion: UK type 2 diabetes patients are at increased risk of a large number of diabetes-
related complications due to an unnecessary delay in insulin initiation. Despite clear guidelines
recommending tight glycaemic control this failure to begin insulin therapy promptly is likely to
result in needlessly reduced life expectancy and compromised quality of life.
Background
The global impact of type 2 diabetes on patients and
healthcare systems is difficult to overstate given the sheer
numbers of individuals with, and the chronic and perva-
sive nature of, the condition. By 2025 it is estimated that
333 million adults will suffer from diabetes [1] and 90%
of these will have type 2 diabetes. Economic conse-
quences for healthcare payers are similarly dramatic with
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the most recent cost estimates in the US alone at $116 bil-
lion for direct costs (pharmacy, hospitalisation, etc) and a
further $58 billion due to lost productivity as a direct con-
sequence of complications arising from the disease [2].
There have been similar findings in Europe where the Cost
of Diabetes in Europe (CODE-2) study estimated total
annual expenditure for type 2 diabetes in eight countries
[3]. Notably both studies highlighted the contribution of
hospitalisation costs as a key driver (responsible for at
least 50% of the total value) [2,4] and the fact that the
costs of treating patients with diabetes are higher than for
those without [2,5]. In the UK alone, it is estimated that
there are over 2.2 million individuals with diabetes and
5% of the total national healthcare budget (over £1 bil-
lion annually) is spent on treatment and management of
the condition [6].
When managing type 2 diabetes the general focus is on
achieving and maintaining good glycaemic control while
minimising the potential for adverse events such as
hypoglycaemia. The value of this approach has been
shown from evidence gained in landmark clinical and epi-
demiological studies where the reduced incidence of
micro- and macrovascular complications was apparent
with intensive glycaemic control [7-14] and has further
been confirmed in a published meta-analysis of observa-
tional studies [15]. To achieve these reductions in the inci-
dence of complications, current UK guidelines from the
National Institute for Health and Clinical Excellence
(NICE) recommend target glycosylated haemoglobin
(HbA1c) levels of between 6.5 and 7.5% (targets that are
in line with guidance from other national and interna-
tional bodies) [16]. Although this dogma has come under
scrutiny and been challenged by some studies [17] it
remains the central principal for the majority of treatment
regimens [18] even if the initiation of insulin is often
resisted by both patients and physicians [19].
Despite published guidance on the management of diabe-
tes it is apparent that many patients fail to receive the
appropriate standard of care (although the reasons are
unclear and blame cannot be easily apportioned). The
magnitude of this issue has been demonstrated by two
studies examining type 2 diabetes management in the UK
primary care setting [20,21]. In these retrospective cohort
studies the authors found that not only were HbA1c meas-
urements poorly recorded for the majority of patients,
regardless of numbers of oral antidiabetic agents (OADs)
prescribed, but even where data were available at least
40% of individuals failed to achieve a modest HbA1c tar-
get of 7.5% [21]. Despite this poor control the average
time spent on monotherapy was 3.8 years and even after
failing to achieve glycaemic control with two or more
OADs the median time before commencing insulin ther-
apy was 7.7 years from initiation of the final OAD [20,21].
This implies an average time to initiation of insulin of at
least 11.5 years from initial diagnosis of type 2 diabetes.
From the published data it is clear then that patients
would not be maintaining their glycaemic control targets
for a substantial proportion of this time. This has the obvi-
ous implication that patients are unnecessarily at an ele-
vated risk of diabetes-related complications.
There are several interesting observations relating to the
management of type 2 diabetes to come from these stud-
ies including: the infrequent measurement of HbA1c
despite clear guidelines that this is the preferred measure
of glycaemic control, the potential therapeutic benefits of
multiple OADs treatment regimens, and the apparent
reluctance of doctor or patient to initiate insulin. We have
chosen to focus this investigation on the seemingly pro-
tracted delay to the initiation of insulin that UK patients
are exposed to and it's potential consequences. Using a
computer simulation model of long-term type 2 diabetes
progression and based on published data the aim of this
analysis was to compare the difference in projected life-
time clinical outcomes for patients immediately initiating
versus delaying initiation of insulin.
Methods
Model
A brief overview of the CORE Diabetes Model is provided
here, but a full description of the model has been previ-
ously published by Palmer et al. [22,23]. The model is a
non-product-specific diabetes policy analysis tool that
takes into account intensive or conventional insulin ther-
apy, oral hypoglycaemic medications, screening and treat-
ment strategies for micro-vascular complications,
treatment strategies for end-stage complications and
multi-factorial interventions. Disease progression is based
on a series of inter-dependent sub-models that simulate
progression of disease-related complications (angina,
myocardial infarction, congestive heart failure, stroke,
peripheral vascular disease, diabetic retinopathy, macula
oedema, cataract, hypoglycaemia, ketoacidosis, lactic aci-
dosis, nephropathy, end-stage renal disease, neuropathy,
foot ulcer and amputation) as well as mortality from other
causes. Each sub-model uses time, state and diabetes type-
dependent probabilities derived from published sources.
The reliability of simulated outcomes has been tested,
with results validated against those reported by clinical tri-
als and epidemiological studies [23].
The model reports outcomes in terms of life expectancy
(years), quality-adjusted life expectancy (quality-adjusted
life years), cumulative incidence of complications and
time free of complications. Quality of life outcomes are
calculated using diabetes-specific state and event utilities
from published studies [24-27].BMC Endocrine Disorders 2009, 9:19 http://www.biomedcentral.com/1472-6823/9/19
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Hypothetical Treatment Progressions and Modelling 
Analyses
The simulated treatment and patient inputs were based on
reported data from two recent retrospective cohort studies
of type 2 diabetes management in the UK [20,21]. In the
base case analysis hypothetical UK patients were assigned
to either insulin initiation in year 1 of the simulation,
mimicking the administration of insulin following failure
of OADs to maintain glycaemic control, or after 8 years,
simulating the observed length of delay in line with pub-
lished data [20]. Insulin efficacy in terms of effect on
HbA1c levels, weight change and hypoglycaemia event
rates were taken from a recent randomised clinical trial
[28] (Table 1) as they reflect the observed change in
HbA1c levels reported in the cohort study [20]. In order to
simplify the analyses no change in other parameters (e.g.
systolic blood pressure, serum lipids, etc.) were assumed
for either treatment. In line with published evidence from
the UKPDS HbA1c was assumed to increase by 0.15% in
all years [9]. Simulations were performed over a 35 year
time horizon to ensure all outcomes were accounted.
Simulation Cohort and Reported Outcomes
Patient characteristics were taken from published studies
in the UK and are detailed in Table 2. Undiscounted life
expectancy (years), quality-adjusted life expectancy (qual-
ity-adjusted life years), cumulative incidence of complica-
tions and time free of complications were calculated for
each simulation and are reported where appropriate. Full
results of all simulations including all outputs are availa-
ble on request from the authors.
Statistical Methodology and One-Way Sensitivity Analyses
For each simulation performed a cohort of 1,000 patients
was run through the model 1,000 times to address first-
order uncertainty (random variation due to chance
events). No statistical uncertainty around patient or treat-
ment parameters was investigated due to the hypothetical
nature of the analysis, however, one-way sensitivity anal-
yses were performed to investigate the effects of assump-
tions on outcomes. In these scenarios individual aspects
of the simulations were varied where: time to initiation of
insulin was varied between 4 and 8 years; clinical benefits
associated with insulin initiation from two alternative
studies were accounted [28,29]; and no disutilities were
accounted for hypoglycaemia events to highlight the effect
of this on quality of life.
Results
Main Findings
When initiating insulin immediately, life expectancy was
projected to increase by an average of 0.61 years (≈7.5
months) in comparison with a delay to insulin initiation
of 8 years (11.40 versus 10.78 years) (Table 3). Survival
curves show an obvious reduction in mortality after just 4
years of the simulation for those initiating insulin imme-
diately versus delaying initiation, and this remains evi-
dent for the majority of the simulation period (Figure 1).
There is also an improvement in quality-adjusted life
expectancy where a benefit of 0.34 quality-adjusted life
years (QALYs) is associated with immediate versus
delayed initiation of insulin (7.53 versus 7.19 QALYs)
(Table 3). This benefit is projected despite the additional
hypoglycaemia risk individuals who immediately initi-
ated insulin would experience in the first 8 years of the
simulation versus those with delayed initiation (570
events per 100 patient years). Both of these clinical out-
comes are driven by substantial reductions in the cumula-
tive incidence and time to onset of most diabetes-related
complications due to the improvements in glycaemic con-
trol associated with insulin administration (Table 4,
Table 5).
Sensitivity Analyses
In all sensitivity analyses modelled improvements in clin-
ical outcomes for immediate versus delayed initiation of
insulin remained (Table 6). There were substantial bene-
fits in life expectancy even when the time to initiation was
reduced to 6 or 4 years. This difference in life expectancy
for immediate versus delayed insulin initiation fell from
0.61 years in the base case to 0.57 and 0.48 years with a
delay of 6 and 4 years, respectively. Interestingly there was
little difference in quality-adjusted life expectancy for the
same sensitivity analyses where it was reduced from 0.34
QALYs in the base case to 0.33 and 0.28 QALYs for a delay
of 6 and 4 years, respectively. This was driven by the
reduced effect of hypoglycaemia on quality of life offset-
ting the difference in incidence of complications.
Where different treatment effects associated with insulin
were applied the magnitude of improvements in clinical
Table 1: Treatment effects associated with insulin initiation
Scenario HbA1c change (%) BMI change (kg/m2) Hypoglycaemia event rate (per 100 patient years) Reference
Base case -1.30 +1.53 570 [28]
Higher HbA1c -1.98 +3.70 310 [29]
Lower HbA1c -0.80 +1.90 230 [28]
HbA1c -- glycosylated haemoglobin; BMI -- body mass indexBMC Endocrine Disorders 2009, 9:19 http://www.biomedcentral.com/1472-6823/9/19
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outcomes was altered but the overall conclusions were the
same. For an immediate versus 8 year delay in the initia-
tion of insulin the difference in life expectancy was 0.82
and 0.37 years and difference in quality-adjusted life
expectancy was 0.63 and 0.24 QALYs for higher and lower
estimates of HbA1c change, respectively.
If the disutility associated with hypoglycaemic events was
eliminated there was an increase in the improvement in
quality-adjusted life expectancy of 0.21 QALYs compared
to the base case simulation (0.55 versus 0.34 QALYs) for
immediate versus delayed initiation of insulin.
Discussion
Although it may be an unsurprising conclusion to draw
that, improving glycaemic control earlier versus later leads
to clinical benefits over time, the increase in mean life
expectancy of over 7 months projected in this study is
quite substantial. We have presented evidence here that in
the UK setting, in line with published evidence on the
average time spent with poorly or uncontrolled hypergly-
caemia prior to initiating insulin, individuals are pro-
jected to experience improvements in life expectancy,
quality-adjusted life expectancy and a reduced incidence
and delayed onset of complications regardless of the delay
to initiation and assumed efficacy of insulin.
Even though there is a notable risk of hypoglycaemia
which would at least partly offset improvements in qual-
ity-adjusted life expectancy associated with insulin
administration there were still substantial benefits for the
immediate versus delayed initiation of insulin. By per-
forming a sensitivity analysis where no quality of life dis-
utility was accounted for hypoglycaemia events the effect
on outcomes of this consequence of improved glycaemic
control was evaluated. Overall the incidence of hypogly-
caemia associated with insulin therapy led directly to a
decrease in quality-adjusted life expectancy of 0.21 QALYs
compared to the base case analysis (0.55 versus 0.34
QALYs).
Model outcomes have been presented here as undis-
counted values to more clearly demonstrate the potential
outcomes for immediate versus delayed initiation of insu-
lin. Although NICE recommends a discount rate of 3.5%
per annum in the UK setting we have deliberately chosen
not to conduct this study from an economic standpoint,
but rather, relate only the potential clinical benefits that
are foregone by delaying insulin initiation. However, as a
matter of record, where outcomes were discounted the
results for the base case showed a benefit for immediate
versus delayed initiation of insulin in terms of life expect-
ancy of 0.36 years (8.57 versus 8.20 years) and for quality-
adjusted life expectancy of 0.18 QALYs (5.73 versus 5.55
QALYs). Although these discounted figures may not
appear as dramatic as the undiscounted results they still
represent substantial improvements that are in line or bet-
ter than many health interventions seeking market
approval.
Table 2: Simulation cohort baseline characteristics
Characteristic Value Reference
Age (years) 64.2 [20]
Duration of diabetes (years) 4 [21]
Percentage male (%) 55.26 [20]
Clinical parameters
HbA1c (%) 8.16 [20]
SBP (mmHg) 141 [30]
Total cholesterol (mg/dl) 214.5 [30]
HDL-cholesterol (mg/dl) 42.9 [30]
LDL-cholesterol (mg/dl) 128.7 [30]
Triglycerides (mg/dl) 204.7 [30]
BMI (kg/m2)3 0 . 1 [ 2 0 ]
Ethnicity
Proportion White (%) 82 Assumed*
Proportion Black (%) 9 Assumed*
Proportion Asian (%) 9 Assumed*
Comorbidities at baseline
Myocardial infarction (%) 8.2 [31]
Peripheral vascular disease (%) 4.5 [30]
Stroke (%) 6.6 [30]
Congestive heart failure (%) 22.8 [30]
Microalbuminuria (%) 0.7 [31]
End-stage renal disease (%) 1 [31]
Background diabetic retinopathy (%) 17.7 [31]
Neuropathy (%) 6.5 [31]
HbA1c -- glycosylated haemoglobin; SBP -- systolic blood pressure; 
HDL -- high-density lipoprotein; LDL -- low-density lipoprotein; BMI -
- body mass index; * no data found and so assumed
Survival curve for simulated cohort initiating insulin immedi- ately versus delaying for 8 years Figure 1
Survival curve for simulated cohort initiating insulin 
immediately versus delaying for 8 years.
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As noted, this study makes no attempt to quantify the eco-
nomic consequences of delaying insulin initiation. How-
ever there are likely to be direct medical cost savings
associated with immediate initiation of insulin due to dia-
betes-related complications avoided. There are also other
potential cost savings from a societal perspective, e.g. less
need for carers, sustained productivity due to premature
mortality or retirement avoided, etc. that are not
accounted here.
Although the results from this modelling analysis une-
quivocally project improved outcomes for those initiating
insulin and attaining HbA1c targets earlier than currently
observed in the UK there are limitations to the study and
these must be acknowledged. Most obviously this is a
hypothetical modelling study and the outcomes are not
based on randomised controlled clinical trial data (which
would be ethically impossible to acquire). However, the
inputs are based on recent real world data from the UK
setting and where possible all data required to generate
the analyses have been taken from the primary study pub-
lications [20,21] and then supplemented with other UK-
specific data [30,31].
Additionally we have attempted to avoid bias by perform-
ing the analysis without a product-specific focus and it
represents no particular commercial standpoint. In terms
of the tool used to perform the analyses, the computer
simulation model was developed as, and remains, a non-
product-specific decision analysis tool that has been vali-
dated against a number of published clinical trials and
shown to project robust and plausible outcomes [23]. In
order to avoid unnecessary complexity and aid transpar-
ency the analysis was designed to allow minimal opportu-
nities for bias or error (most inputs are unchanged
between comparators) and was simplified where
Table 3: Results of immediate initiation of insulin versus 8 year delay
Immediate Initiation 8-year Delay
Life expectancy (years) 11.40 ± 0.25 10.78 ± 0.24
difference 0.61
Quality-adjusted life expectancy (QALYs) 7.53 ± 0.17 7.19 ± 0.16
difference 0.34
QALY -- quality-adjusted life year; discrepancies are due to rounding
Table 4: Cumulative incidence of diabetes-related complications
Immediate initiation 8-year delay Difference
Complication
Congestive heart failure, onset (%) 29.22 30.08 -0.87
Congestive heart failure, death (%) 26.58 26.26 +0.31
Angina (%) 12.85 13.13 -0.27
Myocardial infarction, event (%) 28.98 33.63 -4.65
Myocardial infarction, death (%) 25.05 28.07 -3.02
Stroke, event (%) 8.60 8.49 +0.12
Stroke, death (%) 4.73 4.62 +0.12
Background retinopathy (%) 14.08 17.70 -3.62
Proliferative retinopathy (%) 0.91 1.22 -0.31
Severe vision loss (%) 4.05 5.28 -1.22
Macular oedema (%) 11.73 14.81 -3.09
Cataract (%) 6.77 7.45 -0.68
Microalbuminuria (%) 18.66 23.21 -4.56
Gross proteinuria (%) 3.97 5.17 -1.20
End-stage renal disease (%) 0.59 0.75 -0.16
Foot ulcer, first (%) 18.22 20.09 -1.87
Foot ulcer, recurrence (%) 18.62 20.54 -1.92
First amputation (%) 4.37 4.72 -0.35
Neuropathy, onset (%) 34.88 40.49 -5.61
Peripheral vascular disease, onset (%) 13.80 15.90 -2.10BMC Endocrine Disorders 2009, 9:19 http://www.biomedcentral.com/1472-6823/9/19
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necessary. For example, treatment effects associated with
insulin in terms of changes to systolic blood pressure and
serum lipids (total cholesterol, high- and low-density
lipoprotein cholesterol and triglycerides) were not mod-
elled. This was intended to both simplify and maintain a
conservative approach as improvements in these parame-
ters were likely to reduce cardiovascular outcomes and
one would predict that this would favour the immediate
versus delayed initiation of insulin scenario.
Another potential criticism of this analysis is that it does
not account any insulin specific effects outside of change
in HbA1c and risk of hypoglycaemia. Although there is a
distinct absence of reliable data regarding safety issues
with insulin, one area that merits specific attention is in
individuals administering insulin subsequent to an MI
event. The published epidemiological data from the DIG-
AMI-2 trial reported a significant increase in the cumula-
tive endpoint of death, reinfarction and stroke (hazard
ratio of 1.42) for those administering insulin subsequent
to an MI event [32]. However, these results are in contrast
to outcomes from the original DIGAMI study [33] and the
two conclusions are challenging to resolve with each
other. As the authors of the post-hoc analysis of the DIG-
AMI-2 trial themselves point out, there is the strong possi-
bility that results may be confounded by unknown
covariates, and in a complex disease such as diabetes this
is a common concern. As there is a limited amount of data
regarding this in the context of the analysis presented here
no attempt has been made to account for a potential
increase in further cardiovascular events following MI
when administering insulin. It should be noted though
Table 5: Time to onset of diabetes-related complications (years)
Complication Immediate initiation 8-year delay Difference
Any complications 3.08 2.33 0.75
Congestive heart failure 8.90 8.32 0.58
Angina 10.47 9.87 0.60
Myocardial infarction 10.04 9.28 0.76
Stroke 10.43 9.86 0.57
Background retinopathy 8.48 7.68 0.80
Proliferative retinopathy 11.30 10.67 0.63
Severe vision loss 11.13 10.43 0.70
Macula oedema 10.48 9.57 0.91
Cataract 10.84 10.17 0.67
Microalbuminuria 10.03 9.04 0.99
Gross proteinuria 11.20 10.51 0.69
End-stage renal disease 11.37 10.76 0.61
Foot ulcer 10.44 9.73 0.71
Amputation 11.19 10.57 0.62
Neuropathy 8.16 7.07 1.09
Peripheral vascular disease 10.12 9.36 0.76
Table 6: Sensitivity analyses results
Life expectancy (years) Quality-adjusted life expectancy (QALY)
Immediate 
Initiation
Delayed Initiation Difference Immediate 
Initiation
Delayed Initiation Difference
Base case 11.40 ± 0.25 10.78 ± 0.24 0.61 7.53 ± 0.17 7.19 ± 0.16 0.34
Initiation of insulin - 6 
year delay
11.40 ± 0.25 10.83 ± 0.25 0.57 7.53 ± 0.17 7.20 ± 0.17 0.33
Initiation of insulin - 4 
year delay
11.40 ± 0.25 10.91 ± 0.25 0.48 7.53 ± 0.17 7.25 ± 0.17 0.28
Higher HbA1c change 11.66 ± 0.27 10.85 ± 0.23 0.82 7.94 ± 0.18 7.31 ± 0.16 0.63
Lower HbA1c change 11.11 ± 0.24 10.74 ± 0.25 0.37 7.48 ± 0.17 7.23 ± 0.17 0.24
No disutility for 
hypoglycaemia
11.40 ± 0.25 10.78 ± 0.24 0.61 7.88 ± 0.17 7.34 ± 0.16 0.55
QALY -- quality-adjusted life expectancy; HbA1c -- glycosylated haemoglobin; discrepancies are due to rounding.BMC Endocrine Disorders 2009, 9:19 http://www.biomedcentral.com/1472-6823/9/19
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that in the base case analysis the time to onset for a first
MI event was greater than the delay to initiation of insulin
and so for the majority of cases there would have been no
difference in outcomes (i.e. both arms would have been
administering insulin).
Additionally, a similar analysis could be carried out
whereby glycaemic control is postulated to be better
maintained by any manner (more appropriate prescrip-
tion of OADs or other pharmaceutical interventions, com-
pliance issues, patient education, physician support, etc.),
however it was decided that with the published evidence
available the use of insulin represented a more realistic
scenario. It should be noted that the publications by Cal-
vert and colleagues which prompted this analysis did not
directly assess the make up of the OAD based regimens
and whether there were any issue with patient compli-
ance. However, glycaemic control measurements for indi-
viduals were often not recorded perhaps indicating a
systematic failure to manage the patients condition
regardless of the intervention used. Regardless of the spe-
cific management practice addressed in this context the
results clearly highlight the potential benefits for type 2
diabetes patients in the UK who attain glycaemic control
targets compared with the current "real world" observa-
tions.
By considering only insulin effects we excluded the possi-
bility that patients may have been prescribed one of the
new classes of diabetes interventions (DPP-IV inhibitor or
GLP-1 agonist) prior to initiating insulin. As these new
compounds reach the market and become available for
prescription they may well be used prior to insulin initia-
tion, however, the data available to us largely predated
their use and so they were not considered in this analysis.
Their use and effect on the glycaemic control of type 2 dia-
betes subjects in the UK remains to be demonstrated.
We have performed this study using a computer simula-
tion model that incorporates risk formula generated from
studies that demonstrated benefits associated with inten-
sive glycaemic control in terms of hard clinical endpoints.
Following on from these findings the attainment and
maintenance of good glycaemic control as judged by
HbA1c measurements is still recommended in most
patient groups by national healthcare bodies. It has to be
acknowledged though that some patients, such as the very
elderly and seriously ill, are unlikely to realise the full
long-term benefit of tight glycaemic control especially
when associated with elevated risk of hypoglycaemia.
There have also been publications questioning the bene-
fits of intensive glycaemic control and the consequences
for cardiovascular outcomes, such as the findings from the
ACCORD study [17]. The cause of the increased mortality
with intensive versus standard therapy in this study have
still to be elucidated but they may indicate that aggressive
titration to very low HbA1c levels is not appropriate for all
(or indeed any) patients. Until there is an adequate expla-
nation and association between the mortality risk and
level of glycaemic control we are unable to effectively
model this outcome with adequate understanding.
An issue not accounted in this study is the findings of an
observational study by Bowker et al. [34] who reported a
significantly higher rate of cancer-related mortality in
patients exposed to sulfonylureas and insulin compared
with patients exposed to metformin. This issue has
received considerable attention recently with the publica-
tion of a study by Hemkens et al. [35] who reported a pos-
itive association between cancer incidence (with diagnosis
of malignant neoplasm defined as the primary endpoint)
and insulin glargine. However, the results were derived
from studies conducted over a relatively short period of
time (5 years), potentially suggesting that insulin
(glargine) may accelerate the rate of development of exist-
ing tumours rather than stimulating malignant transfor-
mation and the formation of new ones [36]. Despite this
concern the FDA has stated that variations in patient char-
acteristics across treatment groups could have driven any
difference in risk and has not acknowledged any con-
firmed link or advised any discontinuation of treatment
[37]. With no firm evidence to link the use of insulin (or
any other diabetes therapy) to increased cancer risk this
has not been addressed in this analysis.
There are other implications that have not been addressed
by this modelling analysis in relation to the management
of diabetes patients that deserve further investigation.
Although not reported in the two studies by Calvert and
colleagues [20,21] there is accumulating evidence that
type 2 diabetes patients are also poorly managed in terms
of blood pressure and cholesterol levels [38-40]. It is
highly likely that further clinical benefits not captured in
this analysis could be realised if these additional patient
management strategies were adhered to. Also, the similar-
ities and differences between the levels of glycaemic con-
trol and time to initiation of insulin in the UK and other
settings are unknown. It is not possible perhaps to trans-
late these results directly to other countries but it would be
surprising indeed if similar trends were not observed else-
where and hence comparable outcomes.
It is known that progression to insulin therapy is often
resisted by both patients and physicians [41]. The fre-
quently cited reasons are both physical and psychological,
for example a fear of injections, an inability to comply
with the regimen or a feeling of failure in managing the
disease so that insulin is now required for effective treat-
ment. Patients themselves are also frequently unaware of
the chronic and progressive nature of their condition andBMC Endocrine Disorders 2009, 9:19 http://www.biomedcentral.com/1472-6823/9/19
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often do not understand the need for changes in therapies
[42]. Regardless of the reasons for it, the consequences of
failing to maintain glycaemic control are severe and this
study clearly demonstrates the potential mortality and
morbidity that could be avoided if guidelines and targets
are adhered to.
Conclusion
The immediate versus delayed initiation of insulin is pro-
jected to lead to substantial improvements in clinical out-
comes over patient lifetimes. Data from the UK have
shown that patients may typically delay the initiation of
insulin by around 8 years despite poor glycaemic control
and as a consequence mean life expectancy is reduced by
over 7 months for each patient.
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